Publications by authors named "B Kahl"
Introduction: Histone deacetylase inhibitors (HDACi) and combination chemotherapy are independently used to treat relapsed/refractory (R/R) lymphoma. In vitro studies suggest that the addition of HDACi to platinum-based chemotherapy is synergistic.
Patients And Methods: We conducted a phase I study of romidepsin, gemcitabine, oxaliplatin and dexamethasone (Romi-GemOxD) in R/R aggressive lymphomas with an expansion cohort in T-cell lymphomas.
Background: There is a significant association between low vitamin D levels at diagnosis of indolent B-cell lymphomas and inferior overall survival (OS). To determine whether supplemental vitamin D improves event-free survival (EFS) in these patients, we conducted a comparative double-blind study of vitamin D vs. placebo.
View Article and Find Full Text PDFJCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFArticle Synopsis
- Progression of disease within 24 months of initial immunochemotherapy (POD24) in follicular lymphoma (FL) is linked to worse patient outcomes, and there is currently no standard treatment for these patients.
- A study of 256 FL patients with POD24 revealed diverse treatment approaches, with bendamustine-rituximab patients mostly receiving R-CHOP therapy and R-CHOP patients opting for aggressive salvage therapy.
- The overall response rate to treatments after POD24 was 66%, with a complete response rate of 40%, while factors like age over 70 and high-risk FLIPI scores worsened overall survival outcomes (73% at 5 years).
Article Synopsis
- - Outcomes for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) are generally poor; however, the FDA approved Loncastuximab-teserine (Lonca) based on the LOTIS-2 trial results for those who have undergone at least two prior treatments.
- - A retrospective study analyzed 187 patients from 21 US centers treated with Lonca, revealing a complete response rate of 14% and an overall response rate of 32%, indicating lower efficacy in a real-world setting compared to the original trial.
- - Patients in this study had higher risk features, including bulky disease and high-grade B-cell histology, leading to poorer median event-free survival (2.1 months